Stay updated on Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page
- Check5 days agoChange DetectedA new site revision label (v3.5.4) has been added, replacing the previous revision (v3.5.3). This indicates a platform update rather than a modification to the study details.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now shows an updated site revision identifier (moving from v3.5.2 to v3.5.3), indicating a platform/version update without altering the study record content.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check63 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check98 days agoChange DetectedThe page adds Revision: v3.4.2, and removes a government funding lapse notice and the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.